HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party
Mikulska, Malgorzata; Penack, Olaf; Wendel, Lotus; Knelange, Nina; Cornelissen, Jan J; Blijlevens, Nicole; Passweg, Jakob; Kroger, Nicolaus; Bruns, Anke; Koenecke, Christian; Bierings, Marc; Piñana, José Luis; Labussiere-Wallet, Helene; Ghesquieres, Herve; Diaz, Miguel Angel; Sampol, Antonia; Averbuch, Diana; de la Camara, Rafael; Styczynski, Jan
(2022) Bone Marrow Transplantation, volume 57, issue 2, pp. 167 - 175
(Article)
Abstract
HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in
... read more
6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Communicable Diseases, Hepatitis E virus/genetics, Humans, Immunocompromised Host, RNA, Retrospective Studies, Ribavirin/therapeutic use, Stem Cell Transplantation/adverse effects, Transplant Recipients, Transplantation, Hematology, Observational Study, Journal Article
ISSN: 0268-3369
Publisher: Nature Publishing Group
Note: Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer Nature Limited.
(Peer reviewed)